Edaravone in the Treatment of Optic Neuritis

Recruiting now · Not applicable

Conditions studied: Optic Neuritis

In brief

Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.

Key facts

Study ID

NCT05540262

Run by

First Affiliated Hospital of Guangxi Medical University

People needed

50

Starts

2022-01-15

Expected to finish

2025-12-31

Last updated by the study team

2025-02-27

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis
• Patients with a first episode of optic neuritis in either eye
• First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone

You may not qualify if…

• Myopia over 6 diopters
• Refractive media opacity affecting assessment of retinal layers and/or visual acuity

Where it is running

• Yi Du — Nanning, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.